Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Freselestat SCHEMBL6746707 | 1.00 | ELANE (1.00) | ELANE | |
| Freselestat SCHEMBL7004023 | 1.00 | ELANE (1.00) | ELANE | |
| SCHEMBL7009087 | 0.93 | ELANE (1.00) | ELANE | |
| SCHEMBL5728743 | 0.92 | ELANE (0.86) | ELANE | |
| SCHEMBL7006422 | 0.92 | ELANE (1.00) | ELANE | |
| SCHEMBL7005603 | 0.92 | ELANE (1.00) | ELANE | |
| SCHEMBL7005967 | 0.92 | ELANE (1.00) | ELANE | |
| SCHEMBL7004970 | 0.92 | ELANE (1.00) | ELANE | |
| SCHEMBL29197371 | 0.88 | ELANE (0.79) | ELANE | |
| SCHEMBL7202424 | 0.88 | ELANE (1.00) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| US-20250064792-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-02-27 | — | — | US | claimed |
| US-20240216353-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-07-04 | — | — | US | claimed |
| WO-2023212288-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230127290-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | US | claimed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| US-20030216324-A1 | Airway mucus secretion inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| US-20030212115-A1 | Remedies for inflammatory bowel diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-13 | — | — | US | claimed |
| EP-1323420-A1 | REMEDIES FOR INFLAMMATORY BOWEL DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-1323419-A1 | AIRWAY MUCUS SECRETION INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | claimed |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | disclosed |
| US-20250264469-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2025-08-21 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250064792-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240382472-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | MEREO BIOPHARMA 4 LIMITED (GB) | 2024-11-21 | — | — | US | disclosed |
| EP-1323420-A1 | REMEDIES FOR INFLAMMATORY BOWEL DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1323419-A1 | AIRWAY MUCUS SECRETION INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6534658-B1 | Intermediates for producing pharmaceuticals | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | disclosed |
| EP-1219608-A1 | PYRIMIDINE DERIVATIVES, PROCESS FOR PREPARING THE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-1162199-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212115-A1 | Remedies for inflammatory bowel diseases | NOS3, TPMT, NOS2 | ELANE 588/4885 |
| US-20240382472-A1 | NEUTROPHIL ELASTASE INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS | SERPINB1, ELANE, MMP8 | ELANE 2/4885 |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | SERPINB1, ELANE, CELA1 | ELANE 2/4885 |
| US-20030216324-A1 | Airway mucus secretion inhibitors | MUC1, CFTR, SERPINB1 | ELANE 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.